References
- Beh SC, Greenberg BM, Frohman T, et al. Transverse myelitis. Neurol Clin. 2013;31(1):79–138.
- Rodríguez Y, Rojas M, Pacheco Y, et al. Guillain-Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. 2018;15(6):547–562.
- Sá MJ. Acute transverse myelitis: a practical reappraisal. Autoimmun Rev. 2009;9(2):128–131.
- Picca A, Berzero G, Bihan K, et al. Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e967.
- Román GC, Gracia F, Torres A, et al. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021;12:653786.
- West TW, Hess C, Cree BA. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 2012;32(2):97–113.
- Akkad W, Salem B, Freeman JW, et al. Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine. Arch Neurol. 2010;67(8):1018–1020.
- Shah S, Patel J, Alchaki AR, et al. Development of transverse myelitis after vaccination, a CDC/FDA vaccine adverse event reporting system (VAERS) study. Neurology. 2018;90(15):1985–2017.
- Kerr DA, Ayetey H. Immunopathogenesis of acute transverse myelitis. Curr Opin Neurol. 2002;15(3):339–347.
- Charabi S, Engell-Noerregaard L, Nilsson AC, et al. Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab. Front Neurol. 2021;12:655283.
- Shimada T, Hoshino Y, Tsunemi T, et al. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord. 2020;37:101447.
- Narumi Y, Yoshida R, Minami Y, et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer. 2018;18(1):95
- Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2021;10:1038.
- Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11.
- Wilson R, Menassa DA, Davies AJ, et al. Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol. 2018;5(5):640–645.
- Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715–720.
- Möhn N, Beutel G, Gutzmer R, et al. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy— review of the literature and future outlook. J Clin Med. 2019;8(11):1777.
- Goss AL, Samudralwar RD, Das RR, et al. ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol. 2021;89(5):856–857.
- Miravalle A, Biller J, Schnitzler E, et al. Neurological complications following vaccinations. Neurol Res. 2010;32(3):285–292.
- Tahir N, Koorapati G, Prasad S, et al. SARS-CoV-2 vaccination-Induced transverse myelitis. Cureus. 2021;13(7):e16624.
- Gao JJ, Tseng HP, Lin CL, et al. Acute transverse myelitis following COVID-19 vaccination. Vaccines (Basel). 2021;9(9):1008.
- Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27(12):2144–2153.
- Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920.
- Khayat-Khoei M, Bhattacharyya S, Katz J, et al. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol. 2021;269:1093–11106.
- Havla J, Schultz Y, Zimmermann H, et al. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neurol. 2022;269(1):54–55.
- Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74.